| Old Articles: <Older 5271-5280 Newer> |
|---|
 |
Chemistry World
November 25, 2008
James Urquhart |
Virus revealed by flipping lipid A drug that flags up virus-infected cells for destruction by the body's own immune system could lead to new, broad-spectrum anti-viral treatments, say US scientists.   |
The Motley Fool
November 25, 2008
Brian Orelli |
Schering's Peacock Imitation The company lays out its pipeline for investors to see; there are some potential blockbusters waiting there. |
The Motley Fool
November 25, 2008
Brian Orelli |
Genentech Exhales The biotech had everything to lose and almost nothing to gain with its recent clinical trial. |
The Motley Fool
November 24, 2008
Brian Orelli |
Bristol Rolls Snake Eyes in Europe European officials reject Bristol-Myers Squibb's breast cancer treatment, Ixempra. |
The Motley Fool
November 24, 2008
Brian Orelli |
Is Amgen's Nplate a Blockbuster? Amgen gets a positive recommendation from European officials for its blood-clotting drug. |
Wall Street & Technology
November 14, 2008
Ivy Schmerken |
Bloomberg Partners with Sermo Online Medical Community to Build Healthcare Marketplace for Investors The new system will provide access to real-time medical information and postings from tens of thousands of practicing physicians. |
Chemistry World
November 21, 2008
Pete Mitchell |
UK drug price deal finalised The new deal is guaranteed to continue for five years - a great relief to the industry. |
The Motley Fool
November 21, 2008
Brian Orelli |
Coughing Is Bad for Amgen's Health Safety concerns halt drug trial, but all is not lost. |
The Motley Fool
November 21, 2008
Brian Orelli |
The Comeback of the Century? AstraZeneca is trying to revive Iressa. |
The Motley Fool
November 21, 2008
Brian Orelli |
Ligand and Glaxo Like the FDA's Answer Good news arrives for blood-clot buster Promacta. |
| <Older 5271-5280 Newer> Return to current articles. |
